Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

9.1%

1 terminated/withdrawn out of 11 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

9%

1 trials in Phase 3/4

Results Transparency

125%

5 of 4 completed trials have results

Key Signals

3 recruiting5 with results

Enrollment Performance

Analytics

N/A
6(85.7%)
Phase 3
1(14.3%)
7Total
N/A(6)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials
NCT06203054Not ApplicableActive Not Recruiting

CLIP-IT Post-Market Study

Role: lead

NCT02088554Not ApplicableActive Not Recruiting

PERIGON Pivotal Trial

Role: lead

NCT04241328Recruiting

Medtronic SYMBIOSIS Post-Market Registry for Patients Undergoing Cardiac Surgery

Role: lead

NCT06506903Not ApplicableActive Not Recruiting

Avalus Ultra Post-Approval Study (PAS)

Role: lead

NCT04073420Recruiting

Medtronic Cardiac Surgery PMCF Registry

Role: lead

NCT03546374Not ApplicableRecruiting

Medtronic Terminate AF Study

Role: lead

NCT00157807Not ApplicableTerminated

Clinical and Economic Consequences of Left Atrial Bipolar Radiofrequency Ablation of Persistent and Permanent Atrial Fibrillation During Cardiac Surgery

Role: lead

NCT03283722Completed

PRESERVE-MITRAL Post-Market Registry

Role: lead

NCT03139721Completed

Medtronic HAMMOCK Post Approval Study

Role: lead

NCT02686814Not ApplicableCompleted

PERIGON Japan Trial

Role: lead

NCT00506493Phase 3Completed

Medtronic Concomitant Utilization of Radio Frequency for Atrial Fibrillation CURE-AF/Persistent

Role: lead

All 11 trials loaded